Targeted drugs plus chemo for advanced osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 49 years old.
- You have osteosarcoma that is either newly diagnosed and has spread to other parts of the body, or has come back after previous treatment.
- You are able to swallow pills whole or have a liquid version available.
- Your blood counts, kidney, liver, and heart function are within safe limits (your doctor can check this).
- You are willing to have a small tumor sample taken before starting treatment and again during surgery (for research).
- You agree to use effective birth control during treatment and for 12 months after stopping, if there is any chance of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
This early-phase study tests sulfatinib in children, teens, and young adults with high-grade osteosarcoma that has returned or does not respond to standard treatment. It may help shrink tumors or control the disease, and it also aims to find safe dosing.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This trial tests whether adding the immunotherapy drug envafolimab to standard chemotherapy before surgery can help treat stage IIb osteosarcoma (a type of bone cancer) that hasn't spread. The goal is to see if this combination makes the tumor shrink more and improves outcomes.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.